File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Phase i study of heat-deployed liposomal doxorubicin during radiofrequency ablation for hepatic malignancies

TitlePhase i study of heat-deployed liposomal doxorubicin during radiofrequency ablation for hepatic malignancies
Authors
KeywordsDoxorubicin
Abdominal pain
Alanine aminotransferase blood level
Alopecia
Anemia
Issue Date2012
PublisherElsevier Inc.. The Journal's web site is located at http://www.jvir.org/
Citation
Journal Of Vascular And Interventional Radiology, 2012, v. 23 n. 2, p. 248-255 How to Cite?
AbstractPurpose: A phase I dose escalation study was performed with systemically delivered lyso-thermosensitive liposomal doxorubicin (LTLD). The primary objectives were to determine the safe maximum tolerated dose (MTD), pharmacokinetic properties, and dose-limiting toxicity (DLT) of LTLD during this combination therapy. Materials and Methods: Subjects eligible for percutaneous or surgical radiofrequency (RF) ablation with primary (n = 9) or metastatic (n = 15) tumors of the liver, with four or fewer lesions as large as 7 cm in diameter, were included. RF ablation was initiated 15 minutes after starting a 30-minute intravenous LTLD infusion. Dose levels between 20 mg/m 2 and 60 mg/m 2 were evaluated. Magnetic resonance imaging, positron emission tomography, and computed tomography were performed at predetermined intervals before and after treatment until evidence of recurrence was seen, administration of additional antitumor treatment was performed, or a total of 3 years had elapsed. Results: DLT criteria were met at 60 mg/m 2, and the MTD was defined as 50 mg/m 2. RF ablation was performed during the peak of the plasma concentrationtime curve in an effort to yield maximal drug deposition. LTLD produced reversible, dose-dependent neutropenia and leukopenia. Conclusions: LTLD can be safely administered systemically at the MTD (50 mg/m 2) in combination with RF ablation, with limited and manageable toxicity. Further evaluation of this agent combined with RF ablation is warranted to determine its role in the management of liver tumors. © 2012 SIR.
Persistent Identifierhttp://hdl.handle.net/10722/144595
ISSN
2015 Impact Factor: 2.57
2015 SCImago Journal Rankings: 1.210
PubMed Central ID
ISI Accession Number ID
Funding AgencyGrant Number
National Cancer Institute
National Institutes of Health (NIH)HHSN261200800001E
Funding Information:

This project has been funded in whole or in part with federal funds from the National Cancer Institute and the Intramural Research Program of the National Institutes of Health (NIH), and is also supported by NIH/Celsion Cooperative Research Development Agreement 01974 and contract no. HHSN261200800001E.

References

 

DC FieldValueLanguage
dc.contributor.authorWood, BJen_HK
dc.contributor.authorPoon, RTen_HK
dc.contributor.authorLocklin, JKen_HK
dc.contributor.authorDreher, MRen_HK
dc.contributor.authorNg, KKen_HK
dc.contributor.authorEugeni, Men_HK
dc.contributor.authorSeidel, Gen_HK
dc.contributor.authorDromi, Sen_HK
dc.contributor.authorNeeman, Zen_HK
dc.contributor.authorKolf, Men_HK
dc.contributor.authorBlack, CDVen_HK
dc.contributor.authorPrabhakar, Ren_HK
dc.contributor.authorLibutti, SKen_HK
dc.date.accessioned2012-02-03T06:15:08Z-
dc.date.available2012-02-03T06:15:08Z-
dc.date.issued2012en_HK
dc.identifier.citationJournal Of Vascular And Interventional Radiology, 2012, v. 23 n. 2, p. 248-255en_HK
dc.identifier.issn1051-0443en_HK
dc.identifier.urihttp://hdl.handle.net/10722/144595-
dc.description.abstractPurpose: A phase I dose escalation study was performed with systemically delivered lyso-thermosensitive liposomal doxorubicin (LTLD). The primary objectives were to determine the safe maximum tolerated dose (MTD), pharmacokinetic properties, and dose-limiting toxicity (DLT) of LTLD during this combination therapy. Materials and Methods: Subjects eligible for percutaneous or surgical radiofrequency (RF) ablation with primary (n = 9) or metastatic (n = 15) tumors of the liver, with four or fewer lesions as large as 7 cm in diameter, were included. RF ablation was initiated 15 minutes after starting a 30-minute intravenous LTLD infusion. Dose levels between 20 mg/m 2 and 60 mg/m 2 were evaluated. Magnetic resonance imaging, positron emission tomography, and computed tomography were performed at predetermined intervals before and after treatment until evidence of recurrence was seen, administration of additional antitumor treatment was performed, or a total of 3 years had elapsed. Results: DLT criteria were met at 60 mg/m 2, and the MTD was defined as 50 mg/m 2. RF ablation was performed during the peak of the plasma concentrationtime curve in an effort to yield maximal drug deposition. LTLD produced reversible, dose-dependent neutropenia and leukopenia. Conclusions: LTLD can be safely administered systemically at the MTD (50 mg/m 2) in combination with RF ablation, with limited and manageable toxicity. Further evaluation of this agent combined with RF ablation is warranted to determine its role in the management of liver tumors. © 2012 SIR.en_HK
dc.languageengen_US
dc.publisherElsevier Inc.. The Journal's web site is located at http://www.jvir.org/en_HK
dc.relation.ispartofJournal of Vascular and Interventional Radiologyen_HK
dc.subjectDoxorubicin-
dc.subjectAbdominal pain-
dc.subjectAlanine aminotransferase blood level-
dc.subjectAlopecia-
dc.subjectAnemia-
dc.titlePhase i study of heat-deployed liposomal doxorubicin during radiofrequency ablation for hepatic malignanciesen_HK
dc.typeArticleen_HK
dc.identifier.emailPoon, RT: poontp@hkucc.hku.hken_HK
dc.identifier.authorityPoon, RT=rp00446en_HK
dc.description.naturelink_to_OA_fulltext-
dc.identifier.doi10.1016/j.jvir.2011.10.018en_HK
dc.identifier.pmid22178041-
dc.identifier.pmcidPMC3264789-
dc.identifier.scopuseid_2-s2.0-84856001228en_HK
dc.identifier.hkuros198350en_US
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-84856001228&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume23en_HK
dc.identifier.issue2en_HK
dc.identifier.spage248en_HK
dc.identifier.epage255en_HK
dc.identifier.isiWOS:000299656600016-
dc.publisher.placeUnited Statesen_HK
dc.identifier.scopusauthoridWood, BJ=7401873523en_HK
dc.identifier.scopusauthoridPoon, RT=7103097223en_HK
dc.identifier.scopusauthoridLocklin, JK=6602997193en_HK
dc.identifier.scopusauthoridDreher, MR=7005303954en_HK
dc.identifier.scopusauthoridNg, KK=35248894000en_HK
dc.identifier.scopusauthoridEugeni, M=23018816900en_HK
dc.identifier.scopusauthoridSeidel, G=14050818100en_HK
dc.identifier.scopusauthoridDromi, S=8927700400en_HK
dc.identifier.scopusauthoridNeeman, Z=36123677800en_HK
dc.identifier.scopusauthoridKolf, M=36137354900en_HK
dc.identifier.scopusauthoridBlack, CDV=35412716000en_HK
dc.identifier.scopusauthoridPrabhakar, R=54684899100en_HK
dc.identifier.scopusauthoridLibutti, SK=7006443836en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats